| Autor: |
Eduardo B, Saad, Ieda P, Costa, Rodrigo E da, Costa, Luiz Antôniuo O, Inácio, Charles, Slater, Angelina, Camiletti, Dario G de, Moura Neto, Paulo, Maldonado, Luiz Eduardo, Camanho, Carisi A, Polanczky |
| Rok vydání: |
2011 |
| Předmět: |
|
| Zdroj: |
Arquivos brasileiros de cardiologia. 97(4) |
| ISSN: |
1678-4170 |
| Popis: |
The ideal management of oral anticoagulation (OAC) before and after catheter ablation for atrial fibrillation (AF) is still controversial.To compare two anticoagulation strategies for catheter ablation for AF: warfarin withholding and use of low-molecular-weight heparin (LMWH); and maintenance of warfarin and therapeutic INR (between 2.0 and 3.0).140 patients (pt) with persistent/permanent AF undergoing catheter ablation for AF were divided into two groups: Group I (70 pt), in which warfarin was withheld five days prior to the procedure and transition to LMWH was used (enoxaparin: 1 mg/kg 2x/day before ablation, and 0.5 mg/kg 2x/day after ablation); Group II (70 pt), in which warfarin was not withheld and the procedure was performed with therapeutic INR. Both groups received intravenous heparin (ACT350 seconds) during ablation.In Group I, one pt (1.4%) had a major hemorrhagic complication and four pts (5.7%) had minor hemorrhagic complications. In Group II, two pts (2.8%) had minor hemorrhagic complications and one pt had a major bleeding, which occurred after using LMWH due to INR2.0. None of the groups had thromboembolic complications or cardiovascular death over a period of 16 ± 8 months.Catheter ablation for AF without withholding OAC and with therapeutic INR is a strategy that has similar safety and efficacy when compared with the traditional transition to LMWH, avoiding the potentially inadequate anticoagulation of the initial post-ablation period. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
